The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

160 reactions · 81 shares | PUT CHEMO TO THE TEST. Oncotype DX® is the only test that knows if chemo is needed for early-stage breast cancer. | Until Everyone Knows | Facebook

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows

1.4K views · 46 reactions | In celebration of the 20th anniversary of Exact Sciences' Oncotype DX® test, we’re exploring its impact with the first patient who used it. | Katie Couric Media | Facebook